← Leaderboards
Matthew Swan Lawrence
Yale University
$1,711,741
Attributed
$3,423,482
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2016–20$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$3,423,482 · 2
By mechanism
R01$2,929,724 · 1
R56$493,758 · 1
Top collaborators
- Tamas L Horvath7 shared
Most similar at Yale University
Same institution · by research overlap
- Tamas L Horvath$33,862,532
- Jennifer Joanne Thomas$3,638,182
- Linda Carol Mayes$17,529,015
- Steve W. C. Chang$12,064,222
- Rajita Sinha$53,551,446
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposAnimalsAgedIn VivoBrainProteinsRejuvenationIn VitroInsightAlcohol Or Other Drugs UseS DiseaseBehaviorAgingMouse ModelPeptidesNonhuman PrimatePublishingBehavioralCohortAging PopulationCardiovascular SystemCaloric RestrictionAttentionCell Aging
Grant awards (7)
In vivo and in vitro systems to validate geronic proteins and their mechanisms of action$519,161
R01 · FY2020 · AG
In vivo and in vitro systems to validate geronic proteins and their mechanisms of action$519,161
R01 · FY2019 · AG
In vivo and in vitro systems to validate geronic proteins and their mechanisms of action$519,161
R01 · FY2018 · AG
Impact of geronic peptides on phenotype development in a rat model of Alzheimer's Disease$418,304
R01 · FY2018 · AG
PET imaging of AD-related markers in non-human primates$417,901
R01 · FY2018 · AG
In vivo and in vitro systems to validate geronic proteins and their mechanisms of action$536,036
R01 · FY2017 · AG
In vivo and in vitro systems to validate geronic proteins and their mechanisms of action$493,758
R56 · FY2016 · AG